NCT05630768CompletedPhase 4
Efficacy and Safety of Actonel® After Denosumab Discontinuation in Postmenopausal Osteoporosis Women
A Multicenter, Open-label, Single-arm Clinical Trial to Evaluate the Efficacy and Safety of Actonel® After Denosumab Discontinuation in Postmenopausal Osteoporosis Women
Source: ClinicalTrials.gov · Last updated 24 Aug 2025
Brief summary (registry, in English)
To evaluate the effect of 1 year of risedronate treatment on the prevention of bone loss after denosumab discontinuation in denosumab-treated post-menopausal osteoporosis for a year
- Status (registry)
- Completed
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 149 (actual)
- First submitted
- 18 Nov 2022
- Start date
- 3 Jan 2023
- Primary completion date
- 23 Jul 2025
- Lead sponsor
- Dong-A ST Co., Ltd.
- Diseases
- Osteoporosis
- NCT number
- NCT05630768
What you commit to
- Study type: Interventional · Phase 4
- Participants enrolled: 149
- From 3 Jan 2023 to the primary completion date, 23 Jul 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Criteria the registry did not label
- Main Inclusion Criteria:
- Postmenopausal women
- Patients diagnosed with postmenopausal osteoporosis and administered denosumab for 1 year
- Main Exclusion Criteria:
- Any contraindication to risedronate
- Those evaluated as inappropriate at the discretion of the investigator
Age in the registry: 50 years to 80 years · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Severance hospital Coordinator of this site? Confirm its status | Seoul | South Korea | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.